DDInter1158 DDInter1004
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Kanamycin
Mesalazine {u} (Compound) causes {v} (Side Effect) Nephrotoxicity
Nephrotoxicity {u} (Side Effect) is caused by {v} (Compound) Kanamycin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) regulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Kanamycin
Mesalazine {u} (Compound) causes {v} (Side Effect) Nephrotoxicity
Nephrotoxicity {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Tobramycin {u} (Compound) resembles {v} (Compound) Kanamycin
Mesalazine {u} (Compound) causes {v} (Side Effect) Albuminuria
Albuminuria {u} (Side Effect) is caused by {v} (Compound) Amikacin
Amikacin {u} (Compound) resembles {v} (Compound) Kanamycin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Kanamycin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Kanamycin
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Mesalazine (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Kanamycin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) regulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Kanamycin (Compound)
Mesalazine (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Tobramycin (Compound) and Tobramycin (Compound) resembles Kanamycin (Compound)
Mesalazine (Compound) causes Albuminuria (Side Effect) and Albuminuria (Side Effect) is caused by Amikacin (Compound) and Amikacin (Compound) resembles Kanamycin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Kanamycin